title: PCSK9 inhibition: A promise fulfilled?
abstract: The association of reduced proprotein convertase subtilisin/kexin type 9 (PCSK9) activity with reduced cardiovascular disease (CVD) events--and the need for add-ons to statin therapy to achieve treatment goals--has led to the rapid development and US Food and Drug Administration (FDA) approval of monoclonal antibody therapies to inhibit PCSK9. Now that PCSK9 inhibitors are approved by the FDA for use in certain patients, data from ongoing long-term clinical trials addressing tolerability, safety, and proof of additional reduction in CVD events are eagerly awaited.
authors.affiliation: Fellow, Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, USA.
authors.forename: Khendi
authors.initials: K
authors.lastname: White
authors.affiliation: Resident, Department of Internal Medicine, Cleveland Clinic, Cleveland, OH, USA.
authors.forename: Chaitra
authors.initials: C
authors.lastname: Mohan
authors.affiliation: Medical Director of Cardiac Rehabilitation and Stress Testing, Section of Preventive Cardiology, Cleveland Clinic, Cleveland, OH, USA.|Staff, Section of Clinical Cardiology and Preventive Cardiology, Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, USA. E-mail: roccom@ccf.org.
authors.forename: Michael
authors.initials: M
authors.lastname: Rocco
mesh_terms: D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D008078:Cholesterol, LDL; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy*; D000091362:PCSK9 Inhibitors; D011092:Polyethylene Glycols / Q000627:therapeutic use; D011506:Proteins / Q000627:therapeutic use; D000071449:Proprotein Convertase 9
chemical_list: D000924:Anticholesteremic Agents; D008078:Cholesterol, LDL; D000091362:PCSK9 Inhibitors; D011092:Polyethylene Glycols; D011506:Proteins; C000590930:BMS-962476; C472125:PCSK9 protein, human; D000071449:Proprotein Convertase 9